Company-diagnostics Stock News

Teladoc Health (TDOC) expects revenues to rise to more than $4 billion in 2024.

Co-Diagnostics (NASDAQ: CODX) has recently received a number of price target changes and ratings updates: 11/15/2021 Co-Diagnostics had its buy rating reaffirmed by analysts at Litchfield Hills Research. 11/15/2021 Co-Diagnostics was upgraded by analysts at Zacks Investment Research from a hold rating to a buy rating. They now have a $10.00 price target []

Co-Diagnostics (NASDAQ:CODX) updated its FY 2021 earnings guidance on Thursday. The company provided earnings per share guidance of $1.070-$1.160 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $0.980. The company issued revenue guidance of $96 million-$100 million, compared to the consensus revenue estimate of $95.21 million. Several brokerages have []

Vanguard Group Inc. increased its position in shares of Co-Diagnostics, Inc. (NASDAQ:CODX) by 1.0% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 1,848,637 shares of the companys stock after purchasing an additional 18,163 shares during the period. Vanguard Group Inc. []

The company absolutely crushed analysts' Q3 estimates.

The stock price of Co-Diagnostics Inc (NASDAQ: CODX) increased by over 6% pre-market today. This is why it happened.

Co-Diagnostics, Inc. (CODX) CEO Dwight Egan on Q3 2021 Results - Earnings Call Transcript

Co-Diagnostics (NASDAQ:CODX) Inc has announced record third-quarter 2021 revenue of $30.1 million, a 38% year-over-year increase, which the company attributed primarily to sales of its Logix Smart cor

Co-Diagnostics (NASDAQ:CODX) Inc has said it will be awarded the 'Innovation Impact Award' at the 2021 BioUtah Life Sciences awards which will be presented on Friday, November 12, 2021, during a virtu

Develops products to detect infectious diseases in humans and animals Offers Logix Smart coronavirus detection test in US and globally Amassed balance sheet of $72.4 million What Co-Diagnostics does:

CoDiagnostics, Inc. (CODX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Co-Diagnostics (NASDAQ:CODX) Inc has announced that its Logix Smart SARS-CoV-2 2-Gene multiplex test is now available for sale in the UK after being validated according to the United Kingdom Health

Co-Diagnostics Inc., revealed that CoSara Diagnostics Pvt Ltd., its joint venture for manufacturing and sales in India, has received clearance from the Central Drugs Standard Control Organization (CD

Co-Diagnostics Inc., revealed that CoSara Diagnostics Pvt Ltd., its joint venture for manufacturing and sales in India, has received clearance from the Central Drugs Standard Control Organization (CD

SALT LAKE CITY, Oct. 6, 2021 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular dia